ClinicalTrials.gg
TerminatedNCT00444639Updated Nov 22, 2019

Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

A Phase 2 interventional study of Triptorelin (Decapeptyl®) in Prostate Cancer, sponsored by Ipsen. Terminated at 15 sites in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-22.

Sponsored by Ipsen · Phase 2, Interventional, and Treatment

Why this study was terminated
Low recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Enrollment
26th of 28
25 · median 120
Started
2007
the only one that year
Phase 2
7 of 28
3 open now
Registered
4th of 28
by date
Lead sponsor
9 of 28
Ipsen

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 26th largest by enrollment, is the only one that started in 2007, is one of 7 in phase 2, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The active ingredient of Pamorelin® 11,25 mg is Triptorelin. Triptorelin is a substitute for a natural hormone produced in the body called Gonadotrophin-releasing hormone (GnRH). GnRH is a hormone secreted by hypothalamus (a gland located in brain) and controls the production of sex hormones (eg testosterone in men) in other organs in the body. The growth of prostate cancer cells, one of the most common cancers in men, is induced by the hormone testosterone. Hormonotherapy is one of treatments available to treat this type of disease by controlling the testosterone serum level. Pamorelin® 11,25 mg is normally injected in the muscle but this type of injection is not suitable for every patient. Therefore the primary purpose of this study is to assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via standard intramuscular (IM) injection based on the percentage of patients presenting a testosterone level ≤ 50 ng/dl at week 24.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological proven prostate cancer, locally advanced or and scheduled to receive hormonal deprivation therapy
  • of more than 9 months
  • Documented testosterone levels of ≥ 125 ng/dl measured by any laboratory or on site within the previous 6 months

Exclusion criteria

Exclusion Criteria:

  • Has a history of to the Medicinal Product or drugs with a similar chemical structure
  • Has previously received a GnRH analogue, estrogens or a steroidal anti -androgen within the last year preceding the study
  • Concomitant anti-coagulation treatment
  • Patient who underwent an orchidectomy or who is scheduled to receive an orchidectomy during the course of this study
  • Patient with known spinal medullar compression
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    1

    triptorelin 11.25mg given 12 weekly by subcutaneous formulation

    Drug: Triptorelin (Decapeptyl®)

  • Active comparator
    2

    triptorelin 11.25mg given 12 weekly by intramuscular injection

    Drug: Triptorelin (Decapeptyl®)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients achieving a plasma testosterone level ≤ 50 ng/dl (1,7 nmol/l).

    Time frame: Week 24

Secondary outcomes

  1. Patient acceptability of the injection; the pain experienced during injection, scored by means of a Visual Analogue Scale (VAS).

    Time frame: Measured at baseline and 12 weeks

  2. Care giver acceptability of the administration of the injection by means of a Visual Analogue Scale (VAS).

    Time frame: Measured at baseline and 12 weeks

  3. Percentage of patients achieving a plasma testosterone level ≤ 50 ng/dl (1,7 nmol/l).

    Time frame: Measured at week 12

07

Study locations

15 sites
  • Vrije Universiteit Medisch Centrum
    Amsterdam, 1081 HV, Netherlands
  • AMC Amsterdam
    Amsterdam, 1105 AZ, Netherlands
  • Alysis Zorggroep Loc. Rijnstate
    Arnhem, 6815 AD, Netherlands
  • Maasziekenhuis Pantein
    Boxmeer, 5831 HA, Netherlands
  • Deventer Ziekenhuis
    Deventer, 7415 EH Deventer, Netherlands
  • Ziekenhuis Gelderse Vallei
    Ede, 61717, Netherlands
  • St. Anna Ziekenhuis Geldrop
    Geldrop, 5664 EH, Netherlands
  • Groen Hart Ziekenhuis
    Gouda, 2803 HH, Netherlands
  • Ziekenhuis Hilversum
    Hilversum, 1213 XZ, Netherlands
  • Westfries Gasthuis Hoorn
    Hoorn, 1642 NP, Netherlands
  • Diaconessenhuis Leiden
    Leiden, 2334 CK, Netherlands
  • Erasmus MC Rotterdam
    Rotterdam, 3015 GD, Netherlands
  • Antonius Ziekenhuis
    Sneek, 8601 ZK, Netherlands
  • UMC Utrecht
    Utrecht, 3584 CX, Netherlands
  • Albert Schweitzer Ziekenhuis
    Zwijndrecht, 3331 LZ, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Feb 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2007
First posted
Mar 8, 2007
Start
Feb 2007
Primary completionActual
Feb 2008
CompletionActual
Jun 2008
Last update
Nov 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00444639
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Mar 8, 2007
Start date
Feb 2007
Primary completion
Feb 2008
Completion
Jun 2008
Last update
Nov 22, 2019

Study contacts

Ipsen Medical Director
study director · Ipsen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion